Anthem Biosciences Ltd
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
- Market Cap ₹ 45,947 Cr.
- Current Price ₹ 818
- High / Low ₹ 865 / 702
- Stock P/E 102
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 28.5 %
- ROE 20.8 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 21.0%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | |
| 451 | 695 | 666 | 626 | 914 | 1,173 | |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% |
| 21 | 37 | 49 | 139 | 63 | 85 | |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 |
| Profit before tax | 121 | 366 | 546 | 497 | 477 | 657 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% |
| 93 | 271 | 406 | 385 | 367 | 451 | |
| EPS in Rs | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 14% |
| TTM: | 30% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 4% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 21% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 |
| 159 | 100 | 35 | 126 | 239 | 113 | |
| 207 | 232 | 228 | 148 | 235 | 284 | |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 |
| 306 | 361 | 329 | 449 | 483 | 705 | |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 |
| 333 | 445 | 863 | 902 | 1,099 | 1,373 | |
| Total Assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 166 | 278 | 333 | 306 | 140 | 418 | |
| -109 | -196 | -205 | -376 | -221 | -152 | |
| -48 | -63 | 181 | 64 | -77 | -134 | |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | 133 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 |
| ROCE % | 55% | 51% | 28% | 24% | 28% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
18 Aug - Earnings Call Transcripts for the Quarter ended June 30, 2025
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
14 Aug - Audio recording of Q1 FY2026 earnings call available on company's website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Aug - Newspaper advertisement confirming dispatch of Postal Ballot Notice
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Aug - Newspaper Advertisement - Unaudited Consolidated and Standalone Financial Results for the Quarter ended June 30, 2025
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 13 Aug
Concalls
-
Aug 2025Transcript PPT REC
Business Overview:[1]
ABL is a Contract Research, Development,
and Manufacturing Organization with fully integrated operations across the drug discovery, development, and manufacturing value chain. It is among the few companies in India offering capabilities in both New Chemical
Entity (NCE) and New Biological Entity (NBE) programs. The company has developed various platforms such as RNA interference (RNAi),
Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides.